CN116693470A - 组胺h3受体抑制剂及其医药用途 - Google Patents
组胺h3受体抑制剂及其医药用途 Download PDFInfo
- Publication number
- CN116693470A CN116693470A CN202310192846.9A CN202310192846A CN116693470A CN 116693470 A CN116693470 A CN 116693470A CN 202310192846 A CN202310192846 A CN 202310192846A CN 116693470 A CN116693470 A CN 116693470A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- groups
- piperidin
- hydroxy
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004384 Histamine H3 receptors Human genes 0.000 title claims abstract description 41
- 108090000981 Histamine H3 receptors Proteins 0.000 title claims abstract description 41
- 239000003112 inhibitor Substances 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 172
- -1 isomer Substances 0.000 claims abstract description 123
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 239000012453 solvate Substances 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 42
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 238000002360 preparation method Methods 0.000 claims description 41
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 35
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 34
- 125000005189 alkyl hydroxy group Chemical group 0.000 claims description 34
- 125000000623 heterocyclic group Chemical group 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 34
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 33
- 125000003545 alkoxy group Chemical group 0.000 claims description 31
- 125000003368 amide group Chemical group 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 30
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 25
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 25
- 150000003462 sulfoxides Chemical class 0.000 claims description 23
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 21
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 21
- 125000005842 heteroatom Chemical group 0.000 claims description 20
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 19
- 125000005360 alkyl sulfoxide group Chemical group 0.000 claims description 19
- 208000004296 neuralgia Diseases 0.000 claims description 19
- 229910052760 oxygen Inorganic materials 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 208000002193 Pain Diseases 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 150000003457 sulfones Chemical class 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 125000005138 alkoxysulfonyl group Chemical group 0.000 claims description 12
- 230000036407 pain Effects 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 11
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 125000003375 sulfoxide group Chemical group 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 208000010877 cognitive disease Diseases 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000030814 Eating disease Diseases 0.000 claims description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 208000003251 Pruritus Diseases 0.000 claims description 3
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 235000014632 disordered eating Nutrition 0.000 claims description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 201000000980 schizophrenia Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 14
- 239000003446 ligand Substances 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 230000003042 antagnostic effect Effects 0.000 abstract description 6
- 238000000034 method Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 description 59
- 238000003786 synthesis reaction Methods 0.000 description 59
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 47
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 40
- 238000005481 NMR spectroscopy Methods 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000007787 solid Substances 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- 238000004809 thin layer chromatography Methods 0.000 description 15
- 239000007858 starting material Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 11
- 241000700159 Rattus Species 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 238000001308 synthesis method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- LNXDUSQEXVQFGP-UHFFFAOYSA-N n-[4-(1-cyclobutylpiperidin-4-yl)oxyphenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(OC2CCN(CC2)C2CCC2)C=CC=1NC(=O)CN1CCOCC1 LNXDUSQEXVQFGP-UHFFFAOYSA-N 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 6
- 229960001233 pregabalin Drugs 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 125000002883 imidazolyl group Chemical group 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 208000029033 Spinal Cord disease Diseases 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000000114 Pain Threshold Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 3
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 3
- 230000037040 pain threshold Effects 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000010189 synthetic method Methods 0.000 description 3
- RGHPCLZJAFCTIK-RXMQYKEDSA-N (R)-2-methylpyrrolidine Chemical compound C[C@@H]1CCCN1 RGHPCLZJAFCTIK-RXMQYKEDSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 2
- PTHDBHDZSMGHKF-UHFFFAOYSA-N 2-piperidin-2-ylethanol Chemical compound OCCC1CCCCN1 PTHDBHDZSMGHKF-UHFFFAOYSA-N 0.000 description 2
- MJOUJKDTBGXKIU-UHFFFAOYSA-N 4,4-difluoropiperidine Chemical compound FC1(F)CCNCC1 MJOUJKDTBGXKIU-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000003840 hydrochlorides Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229940125425 inverse agonist Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- BIWOSRSKDCZIFM-UHFFFAOYSA-N piperidin-3-ol Chemical compound OC1CCCNC1 BIWOSRSKDCZIFM-UHFFFAOYSA-N 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- NNACHAUCXXVJSP-UHFFFAOYSA-N pitolisant Chemical compound C1=CC(Cl)=CC=C1CCCOCCCN1CCCCC1 NNACHAUCXXVJSP-UHFFFAOYSA-N 0.000 description 2
- 229960003651 pitolisant Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BCMYXYHEMGPZJN-UHFFFAOYSA-N 1-chloro-2-isocyanatoethane Chemical compound ClCCN=C=O BCMYXYHEMGPZJN-UHFFFAOYSA-N 0.000 description 1
- WJJKCJYVIICABH-UHFFFAOYSA-N 1-cyclobutylpiperazine Chemical compound C1CCC1N1CCNCC1 WJJKCJYVIICABH-UHFFFAOYSA-N 0.000 description 1
- JIZLSVCSAAZLMG-UHFFFAOYSA-N 1-cyclobutylpiperazine;hydrochloride Chemical compound Cl.C1CCC1N1CCNCC1 JIZLSVCSAAZLMG-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- DJMUYABFXCIYSC-UHFFFAOYSA-N 1H-phosphole Chemical compound C=1C=CPC=1 DJMUYABFXCIYSC-UHFFFAOYSA-N 0.000 description 1
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GPPSQLLIFNWNSB-UHFFFAOYSA-N 3-phenylmethoxycyclobutan-1-one Chemical compound C1C(=O)CC1OCC1=CC=CC=C1 GPPSQLLIFNWNSB-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000004187 Histamine H4 receptors Human genes 0.000 description 1
- 108090000796 Histamine H4 receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-O N-dimethylethanolamine Chemical compound C[NH+](C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-O 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010042928 Syringomyelia Diseases 0.000 description 1
- 206010068268 Tumour compression Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KFHYZKCRXNRKRC-MRXNPFEDSA-N abt-239 Chemical compound C[C@@H]1CCCN1CCC1=CC2=CC(C=3C=CC(=CC=3)C#N)=CC=C2O1 KFHYZKCRXNRKRC-MRXNPFEDSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005257 alkyl acyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007684 eye toxicity Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000327 ocular toxicity Toxicity 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940073599 samelisant Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/38—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种结构全新的组胺H3受体抑制剂,具体涉及该类化合物的游离碱、同分异构体、溶剂化物、及药学上可接受的盐型等结构形式;制备这类化合物的方法;包含该类化合物的组合物及其治疗用途。本发明基于组胺H3受体配体出发,开发了一系列的结构新颖的化合物,并对化合物进行了一系列相关的生物学试验,试验结果均表明该类化合物具有显著的H3受体拮抗活性,可作为先导分子用于预防或治疗与H3受体相关的疾病。
Description
技术领域
本发明属于医药技术领域,涉及一种组胺H3受体抑制剂及其医药用途,具体涉及该类化合物的游离碱、同分异构体、溶剂化物、及药学上可接受的盐型等结构形式;制备这类化合物的方法;包含该类化合物的组合物及其治疗用途。
背景技术
人类基因组计划之后,组胺受体家族已经扩展到四种不同的G蛋白偶联受体(GPCR):H1、H2、H3和H4受体(Nature Review Drug Discovery,2005,4,107-120)。组胺H3受体较大程度上在中枢神经系统中表达并且较小程度上在周围神经系统中表达。
组胺H3受体(H3R)在脑中广泛表达,主要表达于大脑皮质,海马,杏仁核,纹状体等这些与记忆认知能力密切相关的区域。用选择性拮抗剂/反向激动剂阻断这些受体,可以增加神经递质如乙酰胆碱,多巴胺或5-羟色胺的释放,从而调节学习记忆、觉醒与睡眠等多种神经性行为(British Journal of Pharmacology,2008,154(6),1166-1181)。
文献表明组胺H3受体配体可用于治疗认知障碍(British Journal ofPharmacology,2008,154(6),1166-1181)、痴呆(Drug News Perspective,2010,23(2),99-103)、注意缺陷多动障碍、肥胖症(Indian Journal of Pharmacology,2001,(33),17-28)、精神分裂症(Biochemical Pharmacology,2007,73(8),1215-1224)和疼痛(Journal ofPharmacology and Experimental Therapeutics,2011,336(1),30-37)。
目前组胺H3受体配体类化合物,主要分为4(5)位被取代的咪唑环类和非咪唑环类两大类。含有咪唑环的化合物具有低血脑屏障渗透、与细胞色素P-450蛋白相互作用以及肝脏和眼毒性的缺点。非咪唑环类的代表化合物专利:①US20020177589A1公开了可用于调节新型组胺H3受体配体,该发明专利中的化合物可用于治疗阿尔茨海默症、认知障碍。该化合物中代表化合物为ABT-239,在临床实验中具有严重的心脏副作用,使得临床实验终止。②WO2012114348A1公开了作为组胺H3受体配体的新型化合物,该发明化合物可用于治疗多种病症,例如认知障碍、痴呆等。在进入临床的药物中,治疗认知障碍的H3R拮抗剂/反向激动剂Samelisant(SUVN-G3031)目前处于在研状态,目前临床二期适应症为发作性睡病。认知障碍适应症研究于2015-2017年开展临床试验一期,后续无进展。③WO2014030170A1公开了作为组胺H3抑制剂的哒嗪酮衍生物,以及他们作为H3抑制剂的用途,它们的制备方法及其药物组合物。该发明化合物可用于治疗多种病症,例如认知障碍、睡眠/觉醒障碍、饮食障碍等。但是在进行临床实验时,PK/PD数据不理想,使得临床实验终止。
综上所述,目前虽然已公开了一些组胺H3受体配体类化合物,但是迄今为止,在该研发领域就一个获批上市的药物—Pitolisant(H3R拮抗剂/反向激动剂),上市的适应症是嗜睡症。SUVN-G3031等在研药物处于临床2期研究的仍是嗜睡症,认知障碍等神经系统疾病的临床研究已经宣告失败。
因此,亟需寻找和发现结构新颖、安全性高、药效优于Pitolisant、SUVN-G3031等药物的新化学实体,用于预防或治疗与H3靶点相关的疾病,是本领域是技术人员尚未解决的技术难题。
发明内容
本发明旨在提供一种结构全新的组胺H3受体抑制剂,用于预防或治疗与组胺H3受体相关的疾病。
为实现上述发明目的,本发明提供的技术方案具体如下:
一种组胺H3受体抑制剂,为具有如下结构通式Ⅰ的化合物或其药学上可接受的盐:
式中:
W选自-(CH2)m-或-NR6(CH2)m-;
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自-NR’R”、-O(CH2)mNR’R”、取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1、R6各自独立的选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;苯并双环结构包括但不限于苯并杂环;
R7、R8各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基中的一种或几种;
或,R7、R8与共同连接的氮原子成环,且环上的取代基选自如下基团中的一种或几种:氢、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-8元杂环基、3-8元杂芳基;
杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
优选的,为具有如下结构通式Ⅱ的化合物或其药学上可接受的盐:
式中:
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自-NR’R”、-O(CH2)mNR’R”、取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;苯并双环结构包括但不限于苯并杂环;
杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
更优选的,为具有如下结构通式Ⅱ-1的化合物或其药学上可接受的盐:
式中:
X选自O或S;
m选自1或2;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
杂环基、杂芳基中含有至少一个杂原子,杂原子选自N、O或S。
更优选的,为具有如下结构通式Ⅱ-2的化合物或其药学上可接受的盐:
式中:
m选自1或2;
R0选自-NR’R”、-O(CH2)mNR’R”中的一种;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种。
优选的,为具有如下结构通式III的化合物或其药学上可接受的盐:
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R1、R6各自独立的选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5、R6各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;苯并双环结构包括但不限于苯并杂环;
杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
更优选的,为具有如下结构通式III-1的化合物或其药学上可接受的盐:
式中:
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、3-6元环烷基;
R2、R3、R4、R5、R6各自独立的选自氢、卤素、C1-6烷基、氨基、羟基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基中的一种或几种;
所述的杂环基、杂芳基中含有至少一个杂原子,杂原子选自N、O或S。
本发明还提供了一种组胺H3受体抑制剂,包括编号为BIOS-B-1至BIOS-B-31的具有如下结构所示的化合物、同分异构体或其药学上可接受的盐:
BIOS-B-1:2-吗啉-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-2:(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-3:2-(哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-4:2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-5:2-(4,4-二氟哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-6:2-(4-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-7:2-(硫代吗啉-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-8:2-(2-(2-羟乙基)哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-9:2-(哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-10:2-(4-甲基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-11:2-(3-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-12:2-(4-环丁基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
BIOS-B-13:1-(2-吗啉乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-14:(R)-1-(2-(2-甲基吡咯烷-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-15:1-(4-(3-(哌啶-1-基)环丁氧基)苯基)-3-(2-(哌啶-1-基)乙基)脲;
BIOS-B-16:1-(2-(哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-17:1-(2-(N-甲基高哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-18:1-(2-(4,4-二氟哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-19:1-(2-(4-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-20:1-(2-(硫代吗啉-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-21:1-(2-(2-羟乙基)哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-22:1-(2-(4-甲基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-23:1-(2-(3-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-24:1-(2-(4-环丁基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
BIOS-B-25:2-吗啉基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
BIOS-B-26:(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;BIOS-B-27:2-哌啶基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
BIOS-B-28:2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
BIOS-B-29:2-(二乙氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺;
BIOS-B-30:2-(二甲氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺;
BIOS-B-31:2-(2-(二甲氨基)乙氧基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺。
前述编号为BIOS-B-1至BIOS-B-31的化合物或其药学上可接受的盐,具体结构式如下:
进一步的,本发明还提供了一种组胺H3受体抑制剂,包括如下结构所示的手性化合物或其药学上可接受的盐:
(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
(R)-1-(2-(2-甲基吡咯烷-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺。
本发明所述的“化合物”,包括但不限于化合物的如下情形:游离碱、立体异构体、几何异构体、互变异构体、同位素、药学上可接受的盐、溶剂化物、水合物、前药(酯或磷酸酯)等形式。
本发明所述的“化合物”,可以是不对称的,例如,具有一个或多个立体异构体。除非另有说明,所有立体异构体都包括,如对映异构体和非对映异构体。本发明中含有不对称碳原子的化合物,可以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以通过外消旋混合物拆分、使用手性原料或手性试剂合成的方法获得。
本发明所述的“药学上可接受的盐”是指本发明化合物的盐,由本发明发现的具有特定取代基的化合物与相对无毒的碱制备。当本发明的化合物中含有相对酸性的功能团时,可以通过在纯的溶液或合适的惰性溶剂中用足够量的碱与这类化合物的中性形式接触的方式,获得碱加成盐。药学上可接受的碱加成盐,包括但不限于钠、钾、钙、镁盐、铵或有机氨。例如:碱金属盐、碱土金属盐、其他金属盐、无机碱盐、有机碱盐、无机酸盐、低级烷磺酸盐、芳基磺酸盐、有机酸盐、氨基酸盐等。
除了盐的形式,本发明所提供的化合物还存在前药形式。本文所描述的化合物的前药容易地在生理条件下发生化学变化从而转化成本发明的化合物。此外,前体药物可以在体内环境中通过化学或生化方法被转换到本发明的化合物。
含有前述通式结构的化合物,本文中所用的术语具有如下含义:
术语“卤素”,指氟、氯、溴或碘,优选氟、氯或溴。
术语“烷基”,指由碳原子和氢原子组成的直链或支链的饱和烃基团,如C1-6烷基,包括但不限于甲基、乙基、丙基(含正丙基和异丙基)、丁基(含正丁基、异丁基、仲丁基或叔丁基)、戊基(含正戊基、异戊基、新戊基)、正己基、2-甲基己基。
术语“环烷基”,指由碳原子和氢原子组成单环或双环烷基,如C3-8环烷基,包括但不限于环丙基、环丁基、环戊基、环己基、环庚基和环辛基等。
术语“烷氧基”,指通过氧原子相连的直链或支链烷基,如C1-6烷氧基,包括但不限于甲氧基、乙氧基、正丙氧基(含正丙氧基和异丙氧基)、丁氧基(含正丁氧基、异丁氧基、仲丁氧基或叔丁氧基)、戊氧基(含正戊氧基、异戊氧基、新戊氧基)、正己氧基、2-甲基己氧基等。
术语“烷胺基”,指含有氮原子的开链烷基,如C1-6烷胺基,包括但不限于甲胺基、乙胺基、异丙胺基、二甲基胺基、甲基乙基胺基、二乙基胺基等。
术语“芳基”,是指5-12个(整数)碳原子的全碳单环或稠合多环基团,具有完全共轭的π-电子体系,包括但不限于苯环、萘环、蒽环。
术语“杂环基”、“杂芳基”,指具有3-12个(整数)环原子的单环或稠合环,其中有1、2、3个环原子或更多的环原子选自N、O、S中的一个或多个,其余环原子为C,且具有完全共轭或不共轭的π-电子体系。杂环基可以是饱和的、或非饱和的基团。杂环基的实例包括但不限于吡咯基、吲哚基、吡咯烷基、咪唑基、吡唑基、四唑基、吡啶基、喹啉基、异喹啉基、哌啶基、嘧啶基、吡嗪基、哌嗪基、呋喃基、吡喃基、吗啉基。
本发明提供的上述化合物的制备方法,通过以下步骤制备,但不仅限于以下方法:
合成方法1:适用于结构通式Ⅱ,且X=O,R1=H,R0=NR’R”的化合物
反应路线如下:
反应过程如下:
原料1对氟代硝基苯类化合物和中间体1、氢化钠溶于N,N-二甲基甲酰胺中反应,然后在三氟乙酸溶液中反应得到中间体2,随后中间体2与对甲苯磺酰氯进行反应得到中间体3,中间体3与哌啶进行SN2反应得到中间体4,中间体4在Fe粉催化下以氯化铵为氢源、还原成中间体5,中间体5随后被卤代烷基酰氯酰化至中间体6,中间体6经过与胺的取代反应得到中间体7或目标化合物。
中间体1的合成方法如下:
合成方法2:适用于结构通式Ⅲ,且X=O,R1=H,R6=H,R0=NR’R”的化合物
反应路线如下:
反应过程如下:
中间体5与氯代烷基异氰酸酯反应生成中间体8,随后经过与胺的取代反应得到目标化合物。
合成方法3:适用于结构通式Ⅱ,且X=S,R1=H,R0=NR’R”的化合物
反应路线如下:
反应过程如下:中间体7与Lawesson试剂反应得到目标化合物。
前述合成方法1、合成方法2、合成方法3中涉及的取代基R’、R”、R1、R2、R3、R4、R5,定义如下:
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,所述的苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;所述的苯并双环结构包括但不限于苯并杂环;
本发明还提供了一种药物组合物,包含至少一种如前所述的化合物或其药学上可接受的盐作为活性成份,以及至少一种或多种药学上可接受的载体。
本发明所述的“药物组合物”,指一种或多种本发明的化合物或其盐与在本领域中通常接受的用于将生物活性化合物输送至有机体(例如人)的载体的制剂。药物组合物的目的是有利于对有机体给药输送。
本发明所述的化合物或其药学上可接受的盐或其药物组合物的给药途径,包括但不限于口服、直肠、透黏膜、经肠给药,或者局部、经皮、吸入、肠胃外、舌下、阴道内、鼻内、眼内、腹膜内、肌内、皮下、静脉内给药。优选的给药途径是口服给药。
本发明还提供了一种制备如前所述的化合物或药物组合物在预防或治疗与组胺H3受体相关的疾病中的用途。
优选的,前述的药物用于预防或治疗认知障碍、痴呆、注意缺陷多动障碍、精神分裂症、癫痫、睡眠障碍、睡眠呼吸暂停、肥胖、进食障碍、疼痛和瘙痒。
优选的,前述的药物用于预防或治疗神经病理性疼痛,包括但不限于周围性神经病理性疼痛或中枢性神经病理性疼痛。
更优选的,周围性神经病理性疼痛为三叉神经痛、舌咽神经痛、急性或慢性炎性脱髓鞘性多发性神经根神经痛、酒精性多发神经痛、化疗引起的多发性神经痛、复杂性区域痛综合征、嵌压性神经痛(如腕管综合症)、HIV感觉神经痛、医源性神经痛(如乳腺切除术后疼痛)、肿瘤压迫或浸润神经痛、营养缺陷相关性神经痛、糖尿病性神经痛、幻肢痛、疱疹后神经痛、放疗后神经丛痛病、神经根病(颈、胸或腰骶)、毒物接触相关性神经痛或创伤后神经痛。
更优选的,中枢性神经病理性疼痛为卒中后疼痛、多发性硬化相关性疼痛、帕金森病相关性疼痛、创伤后脊髓损伤性疼痛、脊髓空洞症、缺血后脊髓病、压迫性脊髓病、HIV脊髓病或放射后脊髓病。
与现有技术相比,本发明有益效果如下:
本发明基于组胺H3受体配体出发,开发了一系列的结构新颖的组胺H3受体抑制剂,该系列化合物具有制备路线简单,原料易得的特点,并对化合物进行了一系列相关的生物学试验,试验结果均表明该类化合物具有显著的H3受体拮抗活性,可作为先导分子用于预防或治疗与H3受体相关的疾病。
附图说明
图1为各实验组在不同时间和不同剂量下的机械刺痛阈值变化图。图中,与model组比较,*,P<0.05;**,P<0.01;与sham组比较,#,P<0.05;##,P<0.01。
图2为各实验组在不同时间下的机械刺痛阈值变化图。图中,与model组比较,*,P<0.05;**,P<0.01;与sham组比较,#,P<0.05;##,P<0.01。
具体实施方式
以下是本发明的具体实施例,对本发明的技术方案做进一步的描述,但是本发明的保护范围并不限于这些实施例。凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
本发明实施例中涉及的溶剂、设备,代号及全称具体如下:
代号Bn:指基团苄基;
代号DMF:指试剂N,N-二甲基甲酰胺;
代号TFA:指试剂三氟乙酸;
代号TsCl:指试剂对甲苯磺酰氯;
代号TEA:指试剂三乙胺;
代号DCM:指试剂二氯甲烷;
代号Boc:指基团叔丁氧羰基;
代号Lawesson reagent:2,4-双(对甲氧苯基)-1,3-二硫一二磷杂环丁烷-2,4硫化物。
本发明提供的目标化合物制备方法中,液相色谱采用WatersSymmetry C18色谱柱。薄层色谱采用GF254(0.25毫米)。核磁共振色谱(NMR)使用Bruker-400核磁共振仪测定;液质连用(LC/MS)使用Waters ZQ质谱检测器(柱子:WatersSymmetry C18,毫米,5微米,35℃),采用ESI(+)离子模式。
此外,凡涉及易氧化或易水解的原料的所有操作都在氮气保护下进行。除非另有说明,本发明使用的原料都是市售原料、无需进一步纯化可以直接使用。
本发明实施例中涉及的各反应原料、共用中间体等均可通过市售购得或自制获得,其中需要自制获得的原料和共用中间体,制备过程详述如下。
一、原料化合物2的制备:
在共用中间体B1制备过程中涉及的原料化合物2系申请人自制获得,合成路线如下:
在250mL茄形瓶中加入3-(苄氧基)环丁酮(5.0g,28.37mmol)和无水甲醇(34mL),混匀,氮气置换三次,转移至冰水浴降温15min,分批加入硼氢化钠粉末(717mg/批,3批,56.75mmol),0.5h内加毕,最后转移至室温下反应4~5h。薄层色谱检测原料反应完全。反应液加食盐水(1.0mL)淬灭,浓缩干,加入乙酸乙酯搅拌后分层,水相再用乙酸乙酯萃取两次,合并有机相,食盐水洗涤,无水硫酸钠干燥,过滤,浓缩干,得到无色油状液体5.31g(即化合物2),收率99%。
MS:179.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ7.38~7.26(m,5H),4.48(s,2H),4.04(t,J=5.6Hz,1H),3.92~3.79(m,1H),3.80(d,J=4.4Hz,1H),2.35~2.30(m 2H),2.03~1.99(m,2H).
二、共用中间体B1的制备:
中间体B1的合成路线如下:
步骤1:3-(4-硝基苯氧基)环丁醇(3)的合成
化合物2(2.155g,12.09mmol)溶于无水N,N-二甲基甲酰胺15mL中,转移至冰水浴降温5min后,在氮气保护下加入氢化钠(580mg,14.51mmol),冰水浴反应0.5~1h。缓慢滴加对氟硝基苯(化合物1,1.54g)和无水N,N-二甲基甲酰胺5mL的溶液,15min中内滴加完毕。在室温下反应5~6h,薄层色谱检测原料反应完全。将反应液倒入200mL冰水中淬灭,乙酸乙酯萃取(50mL×3),合并有机相,有机相水洗两遍,饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得到黄色粗品3.89g,收率99%。
将该黄色粗品(3.89g)溶于三氟乙酸40mL中,移至油浴回流3~4h。薄层色谱检测原料反应完全。后将反应液移至冰水浴降温至0℃,滴加氢氧化钠溶液调节pH至中性,乙酸乙酯萃取(70mL×3),合并有机相,有机相经饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得黄色粗品4.4g。快速柱层析纯化(石油醚:乙酸乙酯=2:1),得浅黄色粉末1.358g(即化合物3),收率53.7%。
MS:210.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.19(d,J=9.2Hz,2H),7.05(d,J=9.2Hz,2H),5.26(d,J=6.8Hz,1H),4.43(m,1H),3.87(m,1H),2.91~2.83(m,2H),2.01~1.87(m,2H)。
步骤2:3-(4-硝基苯氧基)4-甲苯磺酸环丁酯(4)的合成
化合物3(4.64g,22.22mmol)、三乙胺9.2mL和对甲基苯磺酰氯(1.86g,33.33mmol)溶于无水二氯甲烷40mL,氮气置换后,移至油浴30℃反应过夜,薄层色谱检测原料反应完全。
后处理:反应液加水20mL淬灭,分层,水相用二氯甲烷萃取(50mL×3),有机相合并,有机相经饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得粗品。最后,用甲基叔丁基醚打浆1~2h,得到白色粉末6.73g(即化合物4),收率83.38%。
MS:364.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.17(s,2H),7.82(d,J=9.0Hz,2H),7.50(d,J=9.0Hz,2H),7.00(d,J=7.8,2H),4.62(t,J=7.0Hz,1H),4.50(t,J=7.0Hz,1H),2.94~2.87(m,2H),2.43(s,3H),2.22~2.15(m,2H)。
步骤3:1-(3-(4-硝基苯氧基)环丁基)哌啶(5)的合成
化合物4(800mg,2.20mmol)和哌啶10mL混合,移至油浴100℃反应过夜。薄层色谱检测原料反应完全。
后处理:反应液降至室温,加入水20mL混匀,乙酸乙酯萃取(50mL×3),有机相合并,有机相经饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得粗品736mg(即化合物5),收率99%。
MS:277.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.28~8.14(d,2H),7.11~6.98(d,2H),4.90~4.85(m,1H),2.91~2.86(m,1H),2.91~2.86(m,3H),2.28~2.14(m,5H),1.55~1.30(m,10H)。
步骤4:4-(3-(哌啶-1-基)环丁氧基)苯胺(6)的合成
化合物5(736mg)、还原铁粉(862mg,7.0eq.)和氯化铵(214mg,3.96mmol)溶于乙醇6mL和水溶液2mL,转移至油浴80℃反应1~2h,薄层色谱检测原料反应完全。
后处理:反应液降至室温,硅藻土过滤,少量乙醇冲洗滤饼,滤液浓缩干,加入碳酸氢钠溶液10mL,乙酸乙酯萃取(20mL×3),合并有机相,有机相经饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得褐色油状粗品583mg(即化合物6),收率99%。
MS:347.2[M+H]+。
步骤5:2-氯-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(B1)的合成
化合物6(852mg,3.46mmol)与三乙胺(961μL,6.92mmol)溶于无水二氯甲烷12mL,冰水浴下加入氯乙酰氯358μL,最后移至室温反应过夜(反应液由黄褐色转为深褐色),薄层色谱检测反应原料反应完全。
后处理:反应液加碳酸氢钠溶液15mL淬灭,二氯甲烷萃取(20mL×3),有机相合并,有机相经饱和食盐水洗涤,无水硫酸钠干燥,浓缩干,得褐色油状粗品1.42g。快速柱层析纯化(石油醚:乙酸乙酯:三乙胺=2:1:0.2),得浅黄色粉末720mg(即化合物B1),收率64.5%。
MS:352.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ10.14(s,1H),7.47(d,2H),6.78(d,2H),4.70~4.65(m,1H),4.21(s,2H),2.91~2.79(m,1H),2.37~2.05(m,8H),1.55~1.32(m,6H).
三、共用中间体B2的制备:
中间体B2的合成路线如下:
化合物6(1.896g,7.70mmol)溶于无水二氯甲烷30mL,冰水浴下搅拌15min降温,低温下加入氯乙基异氰酸酯788μL,最后转移至室温反应5~6h(反应液析出大量白色沉淀)。薄层色谱检测原料反应完全。
后处理:将反应液过滤,少量二氯甲烷冲洗滤饼,滤饼浓缩干,得白色粉末1.894g(即化合物B2),收率73.3%。
MS:352.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.26(d,J=9.0Hz,2H),6.69(d,J=9.0Hz,2H),6.28(t,J=5.8Hz,1H),4.66~4.61(m,1H),3.64(t,J=6.2Hz,2H),3.40(q,J=6.2Hz,2H),2.85(s,1H),2.40~1.98(m,8H),1.60~1.25(m,6H).
以下实施例1~31为本发明所述的BIOS-B系列化合物的游离基和/或其盐酸盐结构的制备例,需要说明的是,除实施例已提及的盐酸盐形式外,BIOS-B系列化合物还可以制备成其它药学上可接受的盐形式,包括但不限于:硫酸盐、硝酸盐、亚硝酸盐、马来酸盐、富马酸盐、甲酸盐、二甲酸盐、乙酸盐……等等,其制备均可从本发明提供的实施例1~31中得到相应的技术启示。
实施例1:2-吗啉-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-1)的合成
合成路线如下:
中间体B1(100mg,0.310mmol)、吗啉(81μL,0.929mmol)与三乙胺323μL溶于乙腈4mL,转移至油浴80℃反应过夜,薄层色谱检测原料反应完全。
将反应液浓缩干,制备板纯化(石油醚:乙酸乙酯:三乙胺=5:4:1),得浅褐色油状液体81mg(即化合物BIOS-B-1),收率69.96%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐白色固体86mg(即化合物BIOS-B-1的盐酸盐),成盐收率88.83%。
MS:374.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.58(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.69~4.64(m,1H),3.70~3.54(m,4H),3.08(s,2H),2.88~2.81(m,1H),2.50~2.46(m,4H),2.37~2.00(m,8H),1.60~1.35(m,6H).
实施例2:(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-2)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的(R)-2-甲基吡咯烷代替实施例1的吗啉,其余制备步骤同实施例1。得到黄褐色油状液体75mg(即化合物BIOS-B-2),收率65.12%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐粉色固体71mg(即化合物BIOS-B-2的盐酸盐),成盐收率79.13%。
MS:372.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.47(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.69~4.64(m,1H),3.38(d,J=15.5Hz,1H),3.11~3.06(m,1H),2.95(d,J=15.5Hz,1H),2.88~2.81(m,1H),2.49~2.03(m,10H),1.97~1.87(m,1H),1.81~1.60(m,2H),1.57~1.29(m,7H),1.06(d,J=6.1Hz,3H).
实施例3:2-(哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-3)的合成
合成路线如下:
中间体B1(100mg,0.310mmol)、哌啶(85μL,0.929mmol)与三乙胺323μL溶于乙腈4mL,转移至油浴80℃反应过夜,薄层色谱检测原料反应完全。
将反应液旋干,制备板纯化(石油醚:乙酸乙酯:三乙胺=5:4:1),得到淡黄色固体100mg(即化合物BIOS-B-3),收率86.82%。
MS:372.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.50(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.02(s,2H),2.95~2.81(m,1H),2.44(t,J=5.3Hz,4H),2.38~2.03(m,8H),1.66~1.31(m,12H).
实施例4:2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-4)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的N-甲基高哌嗪代替实施例1的吗啉,其余制备步骤同实施例1。得到黄色固体92mg(即化合物BIOS-B-4),收率74.09%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐淡黄色固体76mg(即化合物BIOS-B-4的盐酸盐),成盐收率64.89%。
MS:401.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.53(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.64(m,1H),3.23(s,2H),2.87~2.83(m,1H),2.80~2.71(m,4H),2.64~2.56(m,4H),2.38~2.14(m,9H),2.12~2.06(m,2H),1.83~1.71(m,2H),1.56~1.32(m,6H).
实施例5:2-(4,4-二氟哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-5)的合成
合成路线如下:
参考实施例3中化合物BIOS-B-3的合成方法,将本实施例的4,4-二氟哌啶代替实施例3的哌啶,其余制备步骤同实施例3。得到淡黄色固体61mg(即化合物BIOS-B-5),收率69.66%。
MS:408.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.59(s,1H),7.51(d,J=9.0Hz,1H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.17(s,2H),2.87(s,1H),2.64(t,J=5.6Hz,4H),2.40~1.95(m,12H),1.57~1.31(m,6H).
实施例6:2-(4-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-6)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的4-羟基哌啶代替实施例1的吗啉,其余制备步骤同实施例1。得到黄色固体94mg(即化合物BIOS-B-6),收率78.25%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐白色固体99mg(即化合物BIOS-B-6的盐酸盐),成盐收率88.64%。
MS:388.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),4.58(d,J=4.0Hz,1H),3.50~3.45(m,1H),3.04(s,2H),2.91(s,1H),2.76~2.71(m,2H),2.40~2.03(m,10H),1.80~1.68(m,2H),1.60~1.32(m,8H).
实施例7:2-(硫代吗啉-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-7)的合成
合成路线如下:
参考实施例3中化合物BIOS-B-3的合成方法,将本实施例的硫代吗啉代替实施例3的哌啶,其余制备步骤同实施例3。得到淡黄色固体86mg(即化合物BIOS-B-7),收率71.21%。
MS:390.0[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),7.51(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.10(s,2H),2.87(s,1H),2.77~2.74(m,4H),2.73~2.63(m,4H),2.40~2.04(m,8H),1.61~1.32(m,6H).
实施例8:2-(2-(2-羟乙基)哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-8)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的2-哌啶乙醇代替实施例1的吗啉,其余制备步骤同实施例1。得到无色油状液体105mg(即化合物BIOS-B-8),收率81.50%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐白色固体101mg(即化合物BIOS-B-8的盐酸盐),成盐收率81.83%。
MS:416.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.53(s,1H),7.50(d,J=9.1Hz,1H),6.76(d,J=9.1Hz,2H),4.70~4.65(m,1H),4.46(s,1H),3.57~3.38(m,2H),3.26(d,J=16.4Hz,1H),3.05(d,J=16.4Hz,1H),2.93~2.70(m,2H),2.59~2.55(m,1H),2.46~2.16(m,7H),2.13~2.08(m,2H),1.77~1.62(m,3H H),1.54~1.45(m,7H),1.44~1.26(m,4H).
实施例9:2-(哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-9)的合成
合成路线如下:
中间体B1(150mg,0.465mmol)、1-Boc-哌嗪(260mg,1.394mmol)与三乙胺323μL溶于乙腈4mL,转移至油浴80℃反应过夜,薄层色谱检测原料反应完全。
将反应液旋干,制备板纯化(石油醚:乙酸乙酯:三乙胺=5:4:1),得类白色固体性状的中间体179mg;中间体105mg在盐酸-乙酸乙酯中搅拌1~2h,旋干,可制备成盐酸盐白色固体105mg(即化合物BIOS-B-9的盐酸盐),两步收率79.89%。
MS:373.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.27(s,1H),10.72(s,1H),9.82(s,2H),7.56(d,J=9.0Hz,2H),6.83(d,J=9.0Hz,2H),4.92~4.87(m,1H),4.10(s,2H),3.83(d,J=7.9Hz,1H),3.58~3.32(m,8H),2.96~2.89(m,2H),2.73~2.64(m,2H),2.40~2.29(m,2H),1.94~1.65(m,5H),1.40~1.30(m,1H).
实施例10:2-(4-甲基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-10)的合成
合成路线如下:
参考实施例3中化合物BIOS-B-3的合成方法,将本实施例的4-甲基哌嗪代替实施例3的哌啶,其余制备步骤同实施例3。得到淡黄色固体107mg(即化合物BIOS-B-10),收率89.30%。
MS:373.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),7.49(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.06(s,2H),2.86(d,J=7.8Hz,1H),2.42~2.20(m,14H),2.18(s,3H),2.13~2.07(m,2H),1.55~1.32(m,6H).
实施例11:2-(3-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-11)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的3-羟基哌啶代替实施例1的吗啉,其余制备步骤同实施例1。得到褐色油108mg(即化合物BIOS-B-11),收率89.90%。
进一步的,用盐酸-乙酸乙酯搅拌1~2h,旋干,可制备成盐酸盐白色固体108mg(即化合物BIOS-B-11的盐酸盐),成盐收率84.16%。
MS:388.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.54(s,1H),7.50(d,J=9.0Hz,2H),6.76(d,J=9.0Hz,2H),4.82~4.53(m,2H),3.63~3.57(m,1H),3.05(d,J=1.7Hz,2H),2.93~2.81(m,1H),2.73(d,J=10.7,1H),2.57(d,J=10.7,1H),2.39~2.02(m,10H),1.72~1.69(m,2H),1.57~1.34(m,7H),1.30~1.09(m,1H).
实施例12:2-(4-环丁基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺(BIOS-B-12)的合成
合成路线如下:
参考实施例3中化合物BIOS-B-3的合成方法,将本实施例的4-环丁基哌嗪代替实施例3的哌啶,其余制备步骤同实施例3。得到淡黄色固体50mg(即化合物BIOS-B-12),收率37.81%。
MS:427.3[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.52(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.69(s,1H),3.07(s,2H),2.95(s,1H),2.74(s,1H),2.45~2.04(m,12H),2.02~1.87(m,2H),1.78(t,J=9.0Hz,2H),1.70~1.58(m,2H),1.58~1.31(m,7H),1.29~1.20(m,1H),1.16~0.80(m,2H).
实施例13:1-(2-吗啉乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-13)的合成
合成路线如下:
中间体B2(100mg,0.284mmol)、吗啉(75μL,0.853mmol)与三乙胺200μL溶于乙腈4mL,转移至油浴80℃反应过夜。薄层色谱检测原料反应完全。
将反应液浓缩干,制备板纯化(乙酸乙酯:三乙胺=4:1),得黄色固体99mg(即化合物BIOS-B-13),收率86.60%。
MS:403.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.40(s,1H),7.25(d,J=9.0Hz,2H),6.68(d,J=9.0Hz,2H),5.95(t,J=5.4Hz,1H),4.68~4.59(m,1H),3.59(t,J=4.7Hz,4H),3.25~3.15(m,2H),2.95~2.83(m,1H),2.42~2.21(m,12H),2.15~2.05(m,2H),1.55~1.32(m,6H).
实施例14:(R)-1-(2-(2-甲基吡咯烷-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-14)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的(R)-2-甲基吡咯烷代替实施例13的吗啉,其余制备步骤同实施例13。得到白色固体45mg(即化合物BIOS-B-14),收率39.56%。
MS:401.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.25(d,J=8.4Hz,2H),6.68(d,J=8.4Hz,2H),5.94(s,1H),4.63(s,1H),3.09(s,2H),2.84(s,2H),2.40~1.99(m,11H),1.96~1.82(m,1H),1.66(t,J=7.8Hz,2H),1.58~1.20(m,8H),1.04(d,J=4Hz,3H).
实施例15:1-(4-(3-(哌啶-1-基)环丁氧基)苯基)-3-(2-(哌啶-1-基)乙基)脲(BIOS-B-15)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的哌啶代替实施例13的吗啉,其余制备步骤同实施例13。得到白色固体87mg(即化合物BIOS-B-15),收率76.48%。
MS:401.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.25(d,J=9.0Hz,2H),6.68(d,J=9.0Hz,2H),5.92(t,J=5.3Hz,1H),4.68~4.58(m,1H),3.17(q,J=6.0Hz,2H),2.86(s,1H),2.46~2.15(m,12H),2.14~2.03(m,2H),1.58~1.30(m,12H).
实施例16:1-(2-(哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-16)的合成
合成路线如下:
中间体B2(300mg,0.852mmol)、1-Boc-哌嗪(477mg,2.558mmol)与三乙胺600μL溶于乙腈4mL,转移至油浴80℃反应过夜,薄层色谱检测原料反应完全。
将反应液旋干,制备板纯化(乙酸乙酯:三乙胺=4:1),得类白色固体性状的中间体346mg;中间体207mg在盐酸-乙酸乙酯中搅拌1~2h,旋干,可制备成盐酸盐白色固体219mg(即化合物BIOS-B-16的盐酸盐),两步收率50.31%。
MS:402.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ11.35(s,1H),8.42(s,1H),7.27(d,J=9.0Hz,2H),6.69(d,J=9.0Hz,2H),5.95(t,J=5.5Hz,1H),4.68~4.59(m,1H),3.22~3.16(m,2H),2.86(s,1H),2.46~2.15(m,12H),2.14~2.03(m,2H),1.58~1.30(m,10H).
实施例17:1-(2-(N-甲基高哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-17)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的N-甲基高哌嗪代替实施例13的吗啉,其余制备步骤同实施例13。得到黄色固体74mg(即化合物BIOS-B-17),收率60.65%。
MS:430.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.88(s,1H),7.29(d,J=9.0Hz,2H),6.69(d,J=9.0Hz,2H),6.43(t,J=5.3Hz,1H),4.70~4.64(m,1H),3.24~3.21(m,4H),3.18~3.13(m,5H),3.05~3.03(m,2H),2.85(t,J=5.2Hz,2H),2.71(d,J=3.9Hz,5H),2.62~2.58(m,3H),2.18(t,J=9.9Hz,2H),1.99~1.89(m,2H),1.64~1.39(m,6H),1.18(t,J=7.3Hz,1H).
实施例18:1-(2-(4,4-二氟哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-18)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的4,4-二氟哌啶代替实施例13的吗啉,其余制备步骤同实施例13。得到白色固体97mg(即化合物BIOS-B-18),收率78.24%。
MS:437.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.36(s,1H),7.25(d,J=9.0Hz,2H),6.68(d,J=9.0Hz,2H),5.96(t,J=5.5Hz,1H),4.68~4.58(m,1H),3.18(q,J=6.1Hz,2H),2.87(s,1H),2.58~2.51(m,4H),2.45(t,J=6.4Hz,2H),2.37~2.16(m,6H),2.14~2.03(m,2H),2.02~1.88(m,4H),1.56~1.33(m,6H).
实施例19:1-(2-(4-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-19)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的4-羟基哌啶代替实施例13的吗啉,其余制备步骤同实施例13。得到粉色固体97mg(即化合物BIOS-B-19),收率81.99%。
MS:437.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.25(d,J=8.4Hz,2H),6.68(d,J=8.4Hz,2H),5.93(t,J=5.4Hz,1H),4.69~4.59(m,1H),4.57(s,1H),3.45(s,1H),3.16(q,J=6.0Hz,2H),2.93~2.85(m,1H),2.81~2.64(m,2H),2.42~2.16(m,8H),2.14~1.94(m,4H),1.81~1.62(m,2H),1.56~1.29(m,8H).
实施例20:1-(2-(硫代吗啉-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-20)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的硫代吗啉代替实施例13的吗啉,其余制备步骤同实施例13。得到黄色固体103mg(即化合物BIOS-B-20),收率86.64%。
MS:419.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.36(s,1H),7.25(d,J=9.0Hz,2H),6.68(d,J=9.0Hz,1H),5.91(t,J=5.4Hz,1H),4.68~4.58(m,1H),3.17(q,J=6.1Hz,2H),2.92~2.80(m,1H),2.72~2.57(m,8H),2.40(t,J=6.4Hz,2H),2.35~2.16(m,6H),2.14~2.03(m,2H),1.54~1.32(m,6H).
实施例21:1-(2-(2-羟乙基)哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-21)的合成
化合物合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的2-哌啶乙醇代替实施例13的吗啉,其余制备步骤同实施例13。得到黄色固体74mg(即化合物BIOS-B-21),收率58.60%。
MS:445.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.45(s,1H),7.26(d,J=8.9Hz,2H),6.68(d,J=8.9Hz,2H),5.92(t,J=5.4Hz,1H),4.68~4.58(m,1H),4.32(s,1H),3.25~3.12(m,4H),2.86(s,1H),2.46~2.15(m,11H),2.14~2.03(m,2H),1.58~1.30(m,14H).
实施例22:1-(2-(4-甲基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-22)的合成
化合物合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的4-甲基哌嗪代替实施例13的吗啉,其余制备步骤同实施例13。得到黄色固体101mg(即化合物BIOS-B-22),收率85.58%。
MS:416.2[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.45(s,1H),7.27(d,J=8.8Hz,2H),6.70(d,J=8.8Hz,2H),5.97(s,1H),4.68(s,1H),3.22~3.16(m,3H),3.05(s,2H),2.67(s,1H),2.44~2.04(m,14H),1.68~1.32(m,7H),1.29~1.08(m,3H).
实施例23:1-(2-(3-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-23)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的3-羟基哌啶代替实施例13的吗啉,其余制备步骤同实施例13。得到黄色固体103mg(即化合物BIOS-B-23),收率87.06%。
MS:417.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.41(s,1H),7.26(d,J=9.2Hz,2H),6.68(d,J=9.2Hz,2H),5.94(t,J=5.3Hz,1H),4.68~4.61(m,1H),4.61~4.53(m,1H),3.53~3.46(m,1H),3.18~3.12(m,2H),2.91~2.78(m,2H),2.77~2.61(m,2H),2.43~2.17(m,8H),2.14~2.03(m,2H),1.94~1.71(m,3H),1.67~1.57(m,1H),1.54~1.35(m,7H).
实施例24:1-(2-(4-环丁基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲(BIOS-B-24)的合成
合成路线如下:
参考实施例13中化合物BIOS-B-13的合成方法,将本实施例的4-环丁基哌嗪盐酸盐代替实施例13的吗啉,其余制备步骤同实施例13。得到白色固体70mg(即化合物BIOS-B-24),收率54.10%。
MS:456.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ8.42(s,1H),7.25(d,J=9.0Hz,2H),6.67(d,J=9.0Hz,2H),5.92(s,1H),3.18~3.14(m,2H),2.88~2.80(m,1H),2.67(t,J=7.7Hz,1H),2.45~2.01(m,18H),1.93(s,2H),1.82~1.56(m,5H),1.55~1.32(m,6H).
实施例25:2-吗啉基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺(BIOS-B-25)的合成
合成路线如下:
化合物BIOS-B-1(100mg,0.268mmol)与Lawesson Reagent(108mg,0.268mmol)溶于无水1,4-二氧六环4mL,回流反应16h。薄层色谱检测原料反应完全。
将反应液浓缩干,制备板纯化(石油醚:乙酸乙酯:三乙胺=5:4:1),得黄色固体12mg
(即化合物BIOS-B-25),收率11.46%。
MS:390.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.59(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.70~3.54(m,4H),3.14(s,2H),2.88~2.81(m,1H),2.50~2.46(m,4H),2.37~2.00(m,8H),1.60~1.35(m,6H).
化合物BIOS-B-1的合成路线与制备步骤,参考实施例1,此处不赘述。
实施例26:(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺(BIOS-B-26)的合成
合成路线如下:
参考实施例25中化合物BIOS-B-25的合成方法,将本实施例的BIOS-B-2替代实施例25中的BIOS-B-1,其余制备步骤同实施例25。得黄色固体38mg(即化合物BIOS-B-26),收率36.45%。
MS:388.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.47(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.69~4.64(m,1H),3.32(d,J=15.5Hz,1H),3.11~3.06(m,1H),2.90(d,J=15.5Hz,1H),2.88~2.81(m,1H),2.49~2.03(m,10H),1.97~1.87(m,1H),1.81~1.60(m,2H),1.57~1.29(m,7H),1.06(d,J=6.1Hz,3H).
化合物BIOS-B-2的合成路线与制备步骤,参考实施例2,此处不赘述。
实施例27:2-哌啶基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺(BIOS-B-27)的合成
合成路线如下:
参考实施例25中化合物BIOS-B-25的合成方法,将本实施例的BIOS-B-3替代实施例25中的BIOS-B-1,其余制备步骤同实施例25。得黄色固体29mg(即化合物BIOS-B-27),收率27.81%。
MS:388.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.50(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.65(m,1H),3.10(s,2H),2.95~2.81(m,1H),2.44(t,J=5.3Hz,4H),2.38~2.03(m,8H),1.66~1.31(m,12H).
化合物BIOS-B-3的合成路线与制备步骤,参考实施例3,此处不赘述。
实施例28:2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺(BIOS-B-28)的合成
合成路线如下:
参考实施例25中化合物BIOS-B-25的合成方法,将本实施例的BIOS-B-4替代实施例25中的BIOS-B-1,其余制备步骤同实施例25。得黄色固体30mg(即化合物BIOS-B-28),收率37.90%。
MS:417.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.53(s,1H),7.50(d,J=9.0Hz,2H),6.75(d,J=9.0Hz,2H),4.70~4.64(m,1H),3.28(s,2H),2.87~2.83(m,1H),2.80~2.71(m,4H),2.64~2.56(m,4H),2.38~2.14(m,9H),2.12~2.06(m,2H),1.83~1.71(m,2H),1.56~1.32(m,6H).
化合物BIOS-B-4的合成路线与制备步骤,参考实施例4,此处不赘述。
实施例29:2-(二乙氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺(BIOS-B-29)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的二乙胺代替实施例1的吗啉,其余制备步骤同实施例1。得到淡黄色固体69mg(即化合物BIOS-B-29),收率61.95%。
MS:360.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.49(s,1H),7.50(d,J=8.8Hz,2H),6.75(d,J=8.8Hz,2H),4.70~4.65(m,1H),3.18(s,2H),2.95~2.81(m,1H),2.44(t,J=5.5Hz,4H),2.29~2.08(m,8H),1.66~1.26(m,12H).
实施例30:2-(二甲氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺(BIOS-B-30)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的二甲胺盐酸盐代替实施例1的吗啉,其余制备步骤同实施例1。得到淡黄色固体51mg(即化合物BIOS-B-30),收率49.67%。
MS:332.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.56(s,1H),7.51(d,J=8.9Hz,2H),6.77(d,J=8.9Hz,2H),4.70~4.65(m,1H),3.12(s,2H),2.95~2.82(m,1H),2.45(t,J=5.6Hz,4H),2.29~2.08(m,10H),1.66~1.26(m,6H).
实施例31:2-(2-(二甲氨基)乙氧基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺(BIOS-B-31)的合成
合成路线如下:
参考实施例1中化合物BIOS-B-1的合成方法,将本实施例的N,N-二甲基乙醇胺代替实施例1的吗啉,其余制备步骤同实施例1。得到淡黄色固体67mg(即化合物BIOS-B-31),收率57.58%。
MS:376.1[M+H]+。
1H NMR(400MHz,DMSO-d6)δ9.26(s,1H),7.53(d,J=8.6Hz,2H),6.85(d,J=8.6Hz,2H),4.65(t,J=9.9Hz,1H),4.16(s,2H),3.69(t,J=6.7Hz,2H),3.02(t,J=6.3Hz,1H),2.81~2.69(m,5H),2.58~2.43(m,3H),2.36~2.30(m,3H),2.18~2.02(m,3H),1.57~1.38(m,8H).
实施例32:化合物的组胺H3受体拮抗活性
以SUVN-G3031为阳性对照,采用FLIPR测定法(NIH assay guidance manual:HTSAssay Validation-Section 4.3.Analysis(Potency),https://www.ncbi.nlm.nih.gov/books/NBK83783)筛选了所合成的21个目标化合物及1个阳性对照化合物的组胺H3受体拮抗活性,结果见表1。
表1.化合物的组胺H3受体拮抗活性
由表中的受体拮抗活性可知,部分化合物呈现出较强的组胺H3受体抑制活性,大部分化合物活性在5nM时比阳性药SUVN-G3031更佳。
实施例33:化合物的安全性hERG
在心肌细胞中,human Ether-a-go-go Related Gene(hERG)编码的延迟整流钾电流(IKr)通道蛋白抑制是药物导致QT间期延长最重要的机制。hERG因其特殊的分子结构,使其可被多种不同结构的化合物抑制,导致严重的心律失常。据统计,25-40%的先导化合物都显示出不同程度的hERG相关毒性。因此,早期评价化合物对hERG的影响在药物开发过程中至关重要。
在稳定表达hERG离子通道的HEK293细胞株上,通过手动膜片钳技术检测化合物对hERG通道的抑制率,以100nM的hERG抑制剂西沙比利(Cisapride)为对照。
结果如表2所示,化合物BIOS-B-17~BIOS-B-23、BIOS-B-8~BIOS-B-15、BIOS-B-6、BIOS-B-4(10μM)对hERG通道的抑制率低于5%,说明受试化合物基本无hERG抑制活性,即受试化合物的安全性好。
表2.化合物对hERG通道的抑制率
注:“—”表示未测
实施例34:化合物BIOS-B-12和BIOS-B-14的疼痛模型活性数据
SD雄性大鼠(180-200g)右后腿,暴露坐骨神经,在坐骨神经即将分叉的前段,采用无菌铬肠线(4号,直径0.15mm),松结扎4个环,每个环距1-2mm,缝合肌肉和皮肤,建立慢性缩窄性损伤(CCI)模型,假手术组仅暴露坐骨神经不结扎,缝合肌肉和皮肤。3d后观察,第7d用电子测痛仪(IITC-2391)检测机械刺痛阈值,连续2天。
将机械刺痛阈值稳定的CCI模型大鼠随机分为5组,分别为模型组(model)、普瑞巴林(Pre)组(30mg/kg)、BIOS-B-12化合物组(3mg/kg)、BIOS-B-12化合物组(1mg/kg)、BIOS-B-12化合物组(0.3mg/kg),按1mL/100g灌胃给药,假手术组(sham)和模型组(model)灌胃同体积的生理盐水,给药前检测基础值,单次给药后0.5h、1h、2h、4h、6h、24h检测机械刺痛阈值,采用单因素方差分析,T-检验计算p值,结果见图1。
结果表明,对SD大鼠CCI神经病理性疼痛模型,化合物BIOS-B-12在3、1、0.3mg/kg三个剂量分别单次给药,可剂量依赖性地提高CCI模型大鼠的机械刺痛阈值;化合物BIOS-B-12(3mg/kg)给药后0.5h至24h时间点的机械刺痛阈值与模型组有显著性差异(P<0.01);化合物BIOS-B-12(1mg/kg)在给药后0.5h至6h时间点的机械刺痛阈值与模型组有显著性差异(P<0.01);化合物BIOS-B-12(0.3mg/kg)在给药后1至2h时间点的机械刺痛阈值与模型组有显著性差异(P<0.05);普瑞巴林30mg/kg的剂量仅在给药后0.5h至2h提高CCI大鼠的机械刺痛阈值与模型组有显著差异,表明化合物BIOS-B-12作用时间更长,镇痛强度均优于普瑞巴林。
将机械刺痛阈值稳定的CCI模型大鼠随机分为4组,分别为模型组、普瑞巴林(Pre)组(30mg/kg)、BIOS-B-14组(1mg/kg),按1mL/100g灌胃给药,假手术组(sham)和模型组(model)灌胃同体积的生理盐水,给药前检测基础值,单次给药后0.5h、1h、2h、4h、6h检测机械痛阈值,采用单因素方差分析,T-检验计算p值,结果见图2。
结果表明,对SD大鼠CCI神经病理性疼痛模型,化合物BIOS-B-14(1mg/kg)可显著提高CCI模型大鼠的机械刺痛阈值;并在给药后0.5h至4h时间点的机械刺痛阈值与模型组有显著性差异(P<0.05),普瑞巴林30mg/kg的剂量仅在给药后0.5h、1h提高CCI大鼠的机械刺痛阈值与模型组有显著差异,表明化合物BIOS-B-14作用时间更长,优于普瑞巴林。
实施例35:化合物BIOS-B-12和BIOS-B-18的瘙痒模型活性数据
C57BL/6J小鼠,雄性,6-8周。动物随机分组,分为模型(Model)组、BIOS-B-12化合物组(10mg/kg)、BIOS-B-18化合物组(10mg/kg)、地塞米松(Dex)组(3mg/kg),每组7只。地塞米松给药1h、BIOS-B-12给药4h和BIOS-B-18给药1h后,小鼠颈背部皮下注射500μg/50μl组胺,立即观察30min,记录小鼠搔抓次数,并计算抑制率=(模型组-药物组)/模型组×100%。
表3.BIOS-B-12和BIOS-B-18对小鼠搔抓次数的影响
化合物 | 抑制率(%) |
BIOS-B-12 | 36.6 |
BIOS-B-18 | 55.0 |
Dex | 29.3 |
从表3中可知,BIOS-B-12(10mg/kg)和BIOS-B-18(10mg/kg)减少组胺诱导的小鼠搔抓次数,并且与阳性药地塞米松比,BIOS-B-18的药效更加显著。
Claims (12)
1.一种组胺H3受体抑制剂,为具有如下结构通式Ⅰ的化合物或其药学上可接受的盐:
式中:
W选自-(CH2)m-或-NR6(CH2)m-;
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自-NR’R”、-O(CH2)mNR’R”、取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1、R6各自独立的选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,所述的苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;所述的苯并双环结构包括但不限于苯并杂环;
R7、R8各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基中的一种或几种;
或,R7、R8与共同连接的氮原子成环,且环上的取代基选自如下基团中的一种或几种:氢、卤素、C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-8元杂环基、3-8元杂芳基;
所述的杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
2.根据权利要求1所述的组胺H3受体抑制剂,其特征在于,为具有如下结构通式Ⅱ的化合物或其药学上可接受的盐:
式中:
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自-NR’R”、-O(CH2)mNR’R”、取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,所述的苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;所述的苯并双环结构包括但不限于苯并杂环;
所述的杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
3.根据权利要求2所述的组胺H3受体抑制剂,其特征在于,为具有如下结构通式Ⅱ-1的化合物或其药学上可接受的盐:
式中:
X选自O或S;
m选自1或2;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
所述的杂环基、杂芳基中含有至少一个杂原子,杂原子选自N、O或S。
4.根据权利要求2所述的组胺H3受体抑制剂,其特征在于,为具有如下结构通式Ⅱ-2的化合物或其药学上可接受的盐:
式中:
m选自1或2;
R0选自-NR’R”、-O(CH2)mNR’R”中的一种;
R’、R”各自独立的选自氢、C1-6烷基、C1-6烷氧基、卤素、氨基、羟基、羧基、羰基、酰胺基、氰基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基中的一种或几种,且R’、R”不同时为氢;
R1选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种。
5.根据权利要求1所述的组胺H3受体抑制剂,其特征在于,为具有如下结构通式Ⅲ的化合物或其药学上可接受的盐:
式中:
X选自O或S;
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、C1-6烷氧基酰胺基、C1-6烷氧基砜基、C1-6烷氧基亚砜基、3-6元环烷基、3-6元杂环基、芳基、杂芳基;
R1、R6各自独立的选自氢、C1-6烷基、-C(O)-烷基或-S(O)2-烷基;
R2、R3、R4、R5、R6各自独立的选自氢、卤素、C1-6烷基、C2-6烯基、C2-6炔基、氨基、羟基、氰基、酰胺基、砜基、亚砜基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6烷基酰胺基、C1-6烷基砜基、C1-6烷基亚砜基中的一种或几种;
或,R2、R3与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构,所述的苯并双环结构包括但不限于苯并杂环;
或,R4、R5与各自连接的苯环上碳原子共同形成取代或未取代的苯并双环结构;所述的苯并双环结构包括但不限于苯并杂环;
所述的杂环基、杂芳基、苯并杂环中含有至少一个杂原子,杂原子选自N、O或S。
6.根据权利要求5所述的组胺H3受体抑制剂,其特征在于,为具有如下结构通式Ⅲ-1的化合物或其药学上可接受的盐:
式中:
n0、n1选自1、2或3;m选自0、1、2、3、4、5或6;
R0选自取代或未取代的5-8元杂环基、取代或未取代的5-8元杂芳基中的一种;所述的杂环基、杂芳基上的取代基选自如下基团中的一种或几种:C1-6烷基、C1-6烷氧基、C2-6烯基、C2-6炔基、卤素、氨基、羟基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基、C1-6卤代烷氧基、C1-6烷氧基羟基、C1-6烷氧基氨基、3-6元环烷基;
R2、R3、R4、R5、R6各自独立的选自氢、卤素、C1-6烷基、氨基、羟基、C1-6卤代烷基、C1-6烷基羟基、C1-6烷基氨基中的一种或几种;
所述的杂环基、杂芳基中含有至少一个杂原子,杂原子选自N、O或S。
7.一种组胺H3受体抑制剂,为具有如下结构的化合物、同分异构体、溶剂化物或其药学上可接受的盐:
2-吗啉-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(4,4-二氟哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(4-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(硫代吗啉-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(2-(2-羟乙基)哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(4-甲基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(3-羟基哌啶-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
2-(4-环丁基哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
1-(2-吗啉乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(2-甲基吡咯烷-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(4-(3-(哌啶-1-基)环丁氧基)苯基)-3-(2-(哌啶-1-基)乙基)脲;
1-(2-(哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(N-甲基高哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(4,4-二氟哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(4-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(硫代吗啉-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(2-羟乙基)哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(4-甲基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(3-羟基哌啶-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
1-(2-(4-环丁基哌嗪-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
2-吗啉基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
2-哌啶基-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
2-(N-甲基高哌嗪-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺;
2-(二乙氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺;
2-(二甲氨基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺;
2-(2-(二甲氨基)乙氧基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)乙酰胺。
8.一种组胺H3受体抑制剂,为具有如下结构的化合物或其药学上可接受的盐:
(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁氧基)苯基)乙酰胺;
(R)-1-(2-(2-甲基吡咯烷-1-基)乙基)-3-(4-(3-(哌啶-1-基)环丁氧基)苯基)脲;
(R)-2-(2-甲基吡咯烷-1-基)-N-(4-(3-(哌啶-1-基)环丁基氧基)苯基)硫代乙酰胺。
9.一种药物组合物,包含至少一种如权1~8中任一项所述的活性组分及至少一种药学上可接受的载体或赋形剂。
10.一种制备如权利要求1~8中任一项所述的化合物或权8所述的药物组合物在预防或治疗与组胺H3受体相关的疾病中的用途。
11.根据权利要求10所述的用途,其特征在于,所述的药物用于预防或治疗认知障碍、痴呆、注意缺陷多动障碍、精神分裂症、癫痫、睡眠障碍、睡眠呼吸暂停、肥胖、进食障碍、疼痛和瘙痒。
12.根据权利要求10所述的用途,其特征在于,所述的药物用于预防或治疗神经病理性疼痛,包括但不限于周围性神经病理性疼痛或中枢性神经病理性疼痛。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2022102000941 | 2022-03-02 | ||
CN202210200094 | 2022-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116693470A true CN116693470A (zh) | 2023-09-05 |
Family
ID=87842194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310192846.9A Pending CN116693470A (zh) | 2022-03-02 | 2023-03-02 | 组胺h3受体抑制剂及其医药用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116693470A (zh) |
WO (1) | WO2023166351A1 (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020177589A1 (en) * | 2001-03-16 | 2002-11-28 | Cowart Marlon D. | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
SG192858A1 (en) * | 2011-02-23 | 2013-09-30 | Suven Life Sciences Ltd | Novel compounds as histamine h3 receptor ligands |
DK2888243T3 (en) * | 2012-08-23 | 2016-09-26 | Suven Life Sciences Ltd | ACRYLAMIDE COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS |
-
2023
- 2023-03-02 WO PCT/IB2023/000170 patent/WO2023166351A1/zh active Application Filing
- 2023-03-02 CN CN202310192846.9A patent/CN116693470A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2023166351A1 (zh) | 2023-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114901661B (zh) | 新型K-Ras G12C抑制剂 | |
CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
EP4083042A1 (en) | Spiro ring-containing quinazoline compound | |
US20230099858A1 (en) | Pyridopyrimidine derivatives as kras inhibitors | |
JP2023519815A (ja) | スピロ環含有キナゾリン化合物 | |
US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
CN112312904A (zh) | 螺环化合物 | |
JP5888237B2 (ja) | ピラゾロキノリン化合物 | |
JP2022503942A (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
KR101738866B1 (ko) | 안드로겐 수용체 길항제, 항암제로서 사이클릭 n,n'-다이아릴티오우레아 및 n,n'-다이아릴우레아, 이의 제조방법 및 이의 용도 | |
CN113717156B (zh) | Egfr抑制剂、其制备方法及用途 | |
AU2011288876A2 (en) | Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof | |
KR20090114439A (ko) | 아실구아니딘 유도체 | |
ES2670444T3 (es) | [1,2,4]Triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CN106632181A (zh) | 噢哢曼尼希碱类化合物、其制备方法和用途 | |
CN116162099A (zh) | 杂环类衍生物及其制备方法和用途 | |
CN115557949A (zh) | 四环类衍生物、其制备方法及其在医药上的应用 | |
JP5673676B2 (ja) | イミダゾ[1,2−a]ピリジン誘導体 | |
CN116693470A (zh) | 组胺h3受体抑制剂及其医药用途 | |
CN116102533A (zh) | 一种芳杂环类化合物及其应用 | |
CN116693446A (zh) | 苯基脲类衍生物及其医药用途 | |
WO2021149767A1 (ja) | ヘテロ環誘導体 | |
WO2016191911A1 (en) | Pharmaceutical composition and use thereof and methods of treating diseases mediated by hedgehog signaling pathway | |
CA3134491A1 (en) | Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use | |
AU2023228096A1 (en) | Histamine h3 receptor antagonist and medical use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |